SAB Biotherapeutics (SABS) Capital Leases (2020 - 2026)

SAB Biotherapeutics' Capital Leases history runs 7 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• Quarterly Capital Leases fell 4.85% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 4.85% YoY) and the FY2025 annual result came in at $3.1 million, down 4.7% from the prior year.
• Capital Leases was $3.1 million for Q1 2026 at SAB Biotherapeutics, down from $3.1 million in the prior quarter.
• Across five years, Capital Leases topped out at $3.7 million in Q1 2022 and bottomed at $3.1 million in Q1 2026.
• A 5-year average of $3.4 million and a median of $3.4 million in 2024 frame the typical range for Capital Leases.
• Annual changes were most pronounced in 2022 — Capital Leases decreased 3.53% — and 2024, when it dropped 5.9%.
• SAB Biotherapeutics' Capital Leases stood at $3.6 million in 2022, then decreased by 5.82% to $3.4 million in 2023, then dropped by 4.17% to $3.3 million in 2024, then declined by 4.7% to $3.1 million in 2025, then retreated by 1.29% to $3.1 million in 2026.
• Business Quant data shows SABS's Capital Leases at $3.1 million in Q1 2026, $3.1 million in Q4 2025, and $3.2 million in Q3 2025.